Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 2 pages · Chinese
Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Hisun Pharmaceutical
- Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug
- Announcement on Implementation Results of the 4th Share Repurchase and Share Changes
- Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
- Correction Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right
- Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary
Later from Zhejiang Hisun Pharmaceutical
- Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
- Announcement on Estimated Daily Related Party Transactions in 2026
- Announcement on Preliminary Earnings Estimate for Q1 2026
- Indicative Announcement on Convening the 2025 Annual General Meeting
- Report for Q1 2026
Follow Zhejiang Hisun Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Hisun Pharmaceutical